Catalysis product captured in lumazine synthase from the fungal pathogen Candida glabrata

Madhu Shankar, Sigurd M. Wilbanks, Yoshio Nakatani, Brian C. Monk, Joel D A Tyndall

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)

Abstract

Candida glabrata has emerged as an important fungal pathogen with intrinsic resistance to azole drugs. The limited efficacy of and resistance to existing antifungals is driving the need to identify new drug targets. The enzyme 6,7-dimethyl-8-(d-ribityl)lumazine synthase is part of the riboflavin- biosynthesis pathway essential to fungi and bacteria and is a potential drug target for the development of broad-spectrum antifungal drugs. The X-ray crystal structure of recombinant lumazine synthase from C. glabrata was obtained at 2.24 Å resolution and revealed a dimer of homopentamers, with one in five subunits containing a product molecule from the catalytic reaction. 

Original languageEnglish
Pages (from-to)1580-1586
Number of pages7
JournalActa Crystallographica Section D: Biological Crystallography
Volume69
Issue number8
DOIs
Publication statusPublished - Aug 2013
Externally publishedYes

Keywords

  • 6,7-dimethyl-8-(d-ribityl)lumazine
  • Candida glabrata
  • fungal pathogens
  • lumazine synthase

Cite this

Shankar, Madhu ; Wilbanks, Sigurd M. ; Nakatani, Yoshio ; Monk, Brian C. ; Tyndall, Joel D A. / Catalysis product captured in lumazine synthase from the fungal pathogen Candida glabrata. In: Acta Crystallographica Section D: Biological Crystallography. 2013 ; Vol. 69, No. 8. pp. 1580-1586.
@article{4954f280683b4ecd8c87b707a6488d1b,
title = "Catalysis product captured in lumazine synthase from the fungal pathogen Candida glabrata",
abstract = "Candida glabrata has emerged as an important fungal pathogen with intrinsic resistance to azole drugs. The limited efficacy of and resistance to existing antifungals is driving the need to identify new drug targets. The enzyme 6,7-dimethyl-8-(d-ribityl)lumazine synthase is part of the riboflavin- biosynthesis pathway essential to fungi and bacteria and is a potential drug target for the development of broad-spectrum antifungal drugs. The X-ray crystal structure of recombinant lumazine synthase from C. glabrata was obtained at 2.24 {\AA} resolution and revealed a dimer of homopentamers, with one in five subunits containing a product molecule from the catalytic reaction. ",
keywords = "6,7-dimethyl-8-(d-ribityl)lumazine, Candida glabrata, fungal pathogens, lumazine synthase",
author = "Madhu Shankar and Wilbanks, {Sigurd M.} and Yoshio Nakatani and Monk, {Brian C.} and Tyndall, {Joel D A}",
year = "2013",
month = "8",
doi = "10.1107/S0907444913010949",
language = "English",
volume = "69",
pages = "1580--1586",
journal = "Acta Crystallographica Section D: Structural Biology",
issn = "2059-7983",
publisher = "Wiley-Blackwell",
number = "8",

}

Catalysis product captured in lumazine synthase from the fungal pathogen Candida glabrata. / Shankar, Madhu; Wilbanks, Sigurd M.; Nakatani, Yoshio; Monk, Brian C.; Tyndall, Joel D A.

In: Acta Crystallographica Section D: Biological Crystallography, Vol. 69, No. 8, 08.2013, p. 1580-1586.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Catalysis product captured in lumazine synthase from the fungal pathogen Candida glabrata

AU - Shankar, Madhu

AU - Wilbanks, Sigurd M.

AU - Nakatani, Yoshio

AU - Monk, Brian C.

AU - Tyndall, Joel D A

PY - 2013/8

Y1 - 2013/8

N2 - Candida glabrata has emerged as an important fungal pathogen with intrinsic resistance to azole drugs. The limited efficacy of and resistance to existing antifungals is driving the need to identify new drug targets. The enzyme 6,7-dimethyl-8-(d-ribityl)lumazine synthase is part of the riboflavin- biosynthesis pathway essential to fungi and bacteria and is a potential drug target for the development of broad-spectrum antifungal drugs. The X-ray crystal structure of recombinant lumazine synthase from C. glabrata was obtained at 2.24 Å resolution and revealed a dimer of homopentamers, with one in five subunits containing a product molecule from the catalytic reaction. 

AB - Candida glabrata has emerged as an important fungal pathogen with intrinsic resistance to azole drugs. The limited efficacy of and resistance to existing antifungals is driving the need to identify new drug targets. The enzyme 6,7-dimethyl-8-(d-ribityl)lumazine synthase is part of the riboflavin- biosynthesis pathway essential to fungi and bacteria and is a potential drug target for the development of broad-spectrum antifungal drugs. The X-ray crystal structure of recombinant lumazine synthase from C. glabrata was obtained at 2.24 Å resolution and revealed a dimer of homopentamers, with one in five subunits containing a product molecule from the catalytic reaction. 

KW - 6,7-dimethyl-8-(d-ribityl)lumazine

KW - Candida glabrata

KW - fungal pathogens

KW - lumazine synthase

UR - http://www.scopus.com/inward/record.url?scp=84881279315&partnerID=8YFLogxK

U2 - 10.1107/S0907444913010949

DO - 10.1107/S0907444913010949

M3 - Article

VL - 69

SP - 1580

EP - 1586

JO - Acta Crystallographica Section D: Structural Biology

JF - Acta Crystallographica Section D: Structural Biology

SN - 2059-7983

IS - 8

ER -